Editing Scandion Oncology (section)

==== Positioning is key to unlocking SCO-101 value in mCRC ====
Should data from the CORIST clinical trial prove positive, Edison Investment Research expects Scandion to begin positioning SCO-101 in earlier lines of therapy. To this end, the company intends to conduct positioning studies in the second line of treatment for mCRC, likely in combination with FOLFIRI ± VEGF and/or EGFR antibodies, before moving to pivotal Phase III trials. Edison Investment Research believes repositioning SCO-101 to the second line in mCRC could add significant value to SCO-101. Edison Investment Research notes, the small patient group size in CORIST part 2 (n=25) and open-label study design will, in its view, likely require Scandion to perform larger, randomised studies to maximise deal value with potential development partners and/or licensors. The company plans to initiate pivotal Phase II/III trials in second-line mCRC patients in 2023, provided data from Part 2 of CORIST are supportive. Furthermore, as stated previously, in June 2022 management announced its intention to use the proceeds from a rights issue to expand SCO-101 clinical development to RAS-mutant patients.